THERAPY DOSSIER · th-a61b0a0b1415

Lisuride hydrogen maleate

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL157138 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Lisuride; Lisuride maleate; Lysuride maleate; Revanil 200
Note: Not recorded

Clinical trials 4

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00367822 ↗PHASE3completed

Transdermal lisuride phase III efficacy trial in restless legs syndrome

Restless Legs Syndrome

Enrolment: 300 · Results not recorded

NCT00408915 ↗PHASE3completed

Subcutaneous lisuride minipump infusion in advanced Parkinson's disease refractory to oral therapy

Parkinson's Disease

Enrolment: 60 · Results not recorded

NCT00089622 ↗PHASE2completed

Transcutaneous lisuride therapy of Parkinson's disease

Parkinson Disease

Enrolment: 40 · Results not recorded

NCT00000338 ↗PHASE1unknown

Infusion laboratory: protocol 2 (lisuride)

Cocaine-Related Disorders

Enrolment: 2 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21658430 ↗2011No effect reported

Effects of lisuride hydrogen maleate on pericontusional tissue metabolism, brain edema formation, and contusion volume development after experimental traumatic brain injury in rats.

RatTBIControlled cortical impactSprague-DawleyMale

Model: Controlled cortical impact traumatic brain injury

Lisuride had no significant effect on brain tissue metabolism, oedema or contusion volume in the acute and subacute stages after controlled cortical impact in rats.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…